PDF herunterladen
Planta Med 2005; 71(11): 999-1004
DOI: 10.1055/s-2005-871303
Original Paper
Pharmacology
© Georg Thieme Verlag KG Stuttgart · New York

Hyperforin acts as an Angiogenesis Inhibitor in vitro and in vivo

Christoph M. Schempp1 , 5 , Judit Kiss2 , 5 , Vladimir Kirkin3 , Marco Averbeck4 , Birgit Simon-Haarhaus1 , Bernhard Kremer1 , Christian C. Termeer1 , Jonathan Sleeman3 , Jan C. Simon4
  • 1Department of Dermatology, University of Freiburg, Freiburg, Germany
  • 2Department of Dermatology, Semmelweis University, Budapest, Hungary
  • 3Institute of Toxicology and Genetics, Forschungszentrum Karlsruhe, Karlsruhe, Germany
  • 4Department of Dermatology, Venerology and Allergology, University of Leipzig, Leipzig, Germany
  • 5These authors contributed equally to this work
Weitere Informationen

Publikationsverlauf

Received: March 25, 2005

Accepted: May 18, 2005

Publikationsdatum:
19. September 2005 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Hyperforin is a plant compound from Hypericum perforatum that inhibits tumor cell proliferation in vitro by induction of apoptosis. Here, we report that hyperforin also acts as an angiogenesis inhibitor in vitro and in vivo. In vitro, hyperforin blocked microvessel formation of human dermal microvascular endothelial cells (HDMEC) on a complex extracellular matrix. Furthermore, hyperforin reduced proliferation of HDMEC in a dose-dependent manner, without displaying toxic effects or inducing apoptosis of the cells. To evaluate the antiangiogenic activity of hyperforin in vivo, Wistar rats were subcutaneously injected with MT-450 mammary carcinoma cells and were treated with peritumoral injections of hyperforin or solvent. Hyperforin significantly inhibited tumor growth, induced apoptosis of tumor cells and reduced tumor vascularization, as shown by in situ staining of CD31-positive microvessels in the tumor stroma. These data suggest that, in addition to the induction of tumor cell apoptosis, hyperforin can also suppress angiogenesis by a direct, non-toxic effect on endothelial cells.

Key words

Angiogenesis - apoptosis - endothelial cells - microvessels - CD31

References

  • 1 Linde K, Ramirez G, Mulrow C D, Pauls A, Weidenhammer W, Melchart D. St. John’s wort for depression - an overview and metaanalysis of randomized clinical trials.  Br Med J. 1996;  313 253-8
    PubMedSuche in Google Scholar
  • 2 Kaul R. Johanniskraut. Botanik, Inhaltsstoffe, Qualitätskontrolle, Pharmakologie, Toxikologie und Klinik. Stuttgart; Wiss Verlagsges; 2000.
    Suche in Google Scholar
  • 3 Bystrov N S, Chernov B K, Dobrynin V N, Kolosov M N. The structure of hyperforin.  Tetrahedron Lett. 1975;  16 2791-4
    CrossrefPubMedSuche in Google Scholar
  • 4 Maisenbacher P, Kovar K A. Analysis and stability of Hyperici oleum.  Planta Med. 1992;  58 351-4
    Thieme ConnectPubMedSuche in Google Scholar
  • 5 Gurevich A I, Dobrynin V N, Kolosov M N, Popravko S A, Ryabova I D, Chernov B K. et al . Hyperforin, an antibiotic from Hypericum perforatum L.  Antibiotiki. 1971;  16 510-3
    PubMedSuche in Google Scholar
  • 6 Schempp C M, Pelz K, Wittmer A, Schöpf E, Simon J C. Antibacterial activity of hyperforin from St John’s wort, against multiresistant Staphylococcus aureus and Gram-positive bacteria.  Lancet. 1999;  353 2129
    PubMedSuche in Google Scholar
  • 7 Müller W E, Singer A, Wonnemann M, Hafner U, Rolli M, Schäfer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract.  Pharmacopsychiatry. 1998;  31 (Suppl 1) 16-21
    Thieme ConnectPubMedSuche in Google Scholar
  • 8 Albert D, Zundorf I, Dingermann T, Muller W E, Steinhilber D, Werz O. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase.  Biochem Pharmacol. 2002;  64 1767-75
    CrossrefPubMedSuche in Google Scholar
  • 9 Schempp C M, Winghofer B, Lüdtke R, Simon-Haarhaus B, Schöpf E, Simon J C. Topical application of St. John’s wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells.  Br J Dermatol. 2000;  142 979-84
    CrossrefPubMedSuche in Google Scholar
  • 10 Schempp C M, Kirkin V, Simon-Haarhaus B, Kersten A, Kiss J, Termeer C C. et al . Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John’s wort that acts by induction of apoptosis.  Oncogene. 2002;  21 1242-50
    CrossrefPubMedSuche in Google Scholar
  • 11 Hostanska K, Reichling J, Bommer S, Weber M, Saller R. Hyperforin a constituent of St John’s wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines.  Eur J Pharm Biopharm. 2003;  56 121-32
    CrossrefPubMedSuche in Google Scholar
  • 12 Dona M, Dell’Aica I, Pezzato E, Sartor L, Calabrese F, Della Barbera M. et al . Hyperforin inhibits cancer invasion and metastasis.  Cancer Res. 2004;  64 6225-32
    CrossrefPubMedSuche in Google Scholar
  • 13 Uhr J W, Scheuermann R H, Street N E, Vitetta E S. Cancer dormancy: opportunities for new therapeutic approaches.  Nat Med. 1997;  3 505-9
    CrossrefPubMedSuche in Google Scholar
  • 14 Gastl G, Hermann T, Steurer M, Zmija J, Gunsilius E, Unger C, Kraft A. Angiogenesis as a target for tumor treatment.  Oncology. 2001;  54 177-84
    PubMedSuche in Google Scholar
  • 15 Liekens S, de Clercq E, Neyts J. Angiogenesis: regulators and clinical applications.  Biochem Pharmacol. 2001;  61 253-70
    CrossrefPubMedSuche in Google Scholar
  • 16 Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A, Matsuyama K. et al . Tumor angiogenesis and mode of metastasis in patients with colorectal cancer.  Cancer Res. 1997;  57 1043-6
    PubMedSuche in Google Scholar
  • 17 Bicknell R, Harris A L. Mechanisms and therapeutic implications of angiogenesis.  Curr Opin Oncol. 1996;  8 60-5
    PubMedSuche in Google Scholar
  • 18 Carmeliet P, Jain R K. Angiogenesis in cancer and other diseases.  Nature. 2000;  407 249-57
    CrossrefPubMedSuche in Google Scholar
  • 19 Detmar M. Tumor angiogenesis.  J Invest Dermatol Symp Proc. 2000;  5 20-3
    CrossrefPubMedSuche in Google Scholar
  • 20 Pluda J M. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies.  Semin Oncol. 1997;  24 203-18
    PubMedSuche in Google Scholar
  • 21 Twardowski P, Gradishar W J. Clinical trials of antiangiogenic agents.  Curr Opin Oncol. 1997;  9 584-9
    PubMedSuche in Google Scholar
  • 22 Weinstat-Saslow D, Steeg P S. Angiogenesis and colonization in the tumor metastatic process: basic and applied advances.  FASEB J. 1994;  8 401-7
    PubMedSuche in Google Scholar
  • 23 Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Müller M. et al . Effects of PTK787/ZK 222 584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.  Cancer Res. 2000;  60 4819-24
    PubMedSuche in Google Scholar
  • 24 Sleeman J P, Kim U, LePendu J, Howells N, Coquerelle T, Ponta H. et al . Inhibition of MT-450 rat mammary tumour growth by antibodies recognising subtypes of blood group antigen B.  Oncogene. 1999;  8 4485-94
    PubMedSuche in Google Scholar
  • 25 Averbeck M, Braun T, Pfeifer G, Sleeman J P, Dudda J, Martin S F. et al . Early cytoskeletal rearrangement during dendritic cell maturation enhances synapse formation and Ca(2+) signaling in CD8(+) T cells.  Eur J Immunol. 2004;  34 2708-19
    CrossrefPubMedSuche in Google Scholar
  • 26 Schempp C M, Simon-Haarhaus B, Termeer C C, Simon J C. Hypericin photo-induced apoptosis of Jurkat cells involves the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and activation of caspase-8.  FEBS Lett. 2001;  493 26-30
    CrossrefPubMedSuche in Google Scholar
  • 27 Weidner N. Intratumoral microvessel density as a prognostic factor in cancer.  Am J Pathol. 1995;  147 9-19
    PubMedSuche in Google Scholar
  • 28 Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marme D. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.  Cancer Res. 1999;  59 3185-91
    PubMedSuche in Google Scholar
  • 29 Nör J E, Christensen J, Mooney D J, Polverini P J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression.  Am J Pathol. 1999;  154 375-84
    PubMedSuche in Google Scholar
  • 30 del Valle-Perez B, Martinez-Estrada O M, Vilaro S, Ventura F, Vinals F. cAMP inhibits TGFbeta1-induced in vitro angiogenesis.  FEBS Lett. 2004;  569 105-11
    CrossrefPubMedSuche in Google Scholar
  • 31 Ogawa H, Rafiee P, Fisher P J, Johnson N A, Otterson M F, Binion D G. Sodium butyrate inhibits angiogenesis of human intestinal microvascular endothelial cells through COX-2 inhibition.  FEBS Lett. 2003;  554 88-94
    CrossrefPubMedSuche in Google Scholar
  • 32 Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M. et al . Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.  Nat Med. 2002;  8 128-35
    CrossrefPubMedSuche in Google Scholar

Christoph M. Schempp

Department of Dermatology

University of Freiburg

Hauptstrasse 7

79104 Freiburg

Germany

Fax: +49-761-270-6829

eMail: cschempp@haut.ukl.uni-freiburg.de

    www.thieme-connect.de/ejournals/toc/plantamedica